Chevy Chase Trust Holdings, Inc. Alaunos Therapeutics, Inc. Transaction History

Chevy Chase Trust Holdings, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 20, 2021	SELL	$2.63 - $3.67 $44,018 - $61,424	-16,737 Closed	0 $0
Q1 2021 Apr 22, 2021	SELL	$2.82 - $5.6 $33,095 - $65,721	-11,736 Reduced 41.22%	16,737 $60,000
Q4 2020 Feb 12, 2021	BUY	$2.09 - $3.09 $59,508 - $87,981	28,473 New	28,473 $72,000
Q1 2020 May 13, 2020	SELL	$1.9 - $4.98 $9,500 - $24,900	-5,000 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$3.95 - $5.35 $19,750 - $26,750	5,000 New	5,000 $23,000
Q2 2019 Aug 14, 2019	SELL	$3.98 - $6.2 $39,800 - $62,000	-10,000 Closed	0 $0
Q3 2018 Oct 23, 2018	SELL	$2.26 - $3.27 $15,819 - $22,890	-7,000 Reduced 41.18%	10,000 $32,000
Q3 2017 Nov 14, 2017	BUY	$4.99 - $6.57 $84,830 - $111,690	17,000	17,000 $104,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Chevy Chase Trust Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Chevy Chase Trust Holdings, Inc. with notifications on news.